UgradarS, MalkhasyanE, DouglasRS. Teprotumumab for the treatment of thyroid eye disease. Endocr Rev2024;45(6):843–857; doi: 10.1210/endrev/bnae018
3.
ZhangH, SunJ, LiY, et al.IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: The RESTORE-1 randomized clinical trial. JAMA Ophthalmol2025;143(11):964–971; doi: 10.1001/jamaophthalmol.2025.3350
4.
DouglasRS, KahalyGJ, PatelA, et al.Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med2020;382(4):341–352; doi: 10.1056/NEJMoa1910434
5.
SmithTJ, KahalyGJ, EzraDG, et al.Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med2017;376(18):1748–1761; doi: 10.1056/NEJMoa1614949
6.
DouglasRS, CouchS, WesterST, et al.Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab2023;109(1):25–35; doi: 10.1210/clinem/dgad637
7.
HiromatsuY, IshikawaE, KozakiA, et al.A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac2025;55:101464; doi: 10.1016/j.lanwpc.2025.101464
8.
MukitFA, ManleyA, PatelAB, et al.Side effects and adverse events after treatment with teprotumumab for thyroid eye disease: A retrospective observational case series. Cureus2024;16(4):e58585; doi: 10.7759/cureus.58585
SmithTJ, CavidaD, HsuK, et al.Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology2024;131(7):815–826; doi: 10.1016/j.ophtha.2024.01.023
11.
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2025. Diabetes Care2025;48(Suppl 1):S27–S49; doi: 10.2337/dc25-S002
12.
KilpatrickES. Toward a global overview of HbA1c test performance. Clin Chem2018;64(8):1131–1132; doi: 10.1373/clinchem.2018.290965
13.
Expert Panel on Metabolic Syndrome of Chinese Diabetes Society. Recommendations on metabolic syndrome of Chinese diabetes society (Chinese). Chin J Diab2004;12:156–161.
14.
HaSK, LinLY, ChiouCA, et al.Longitudinal glycemic outcomes in patients with thyroid eye disease treated with teprotumumab. Ophthalmic Plast Reconstr Surg2025; doi: 10.1097/IOP.0000000000003126
15.
StanMN, KriegerCC. The adverse effects profile of teprotumumab. J Clin Endocrinol Metab2023;108(9):e654–e662; doi: 10.1210/clinem/dgad213
16.
GallagherEJ, Le RoithD, BloomgardenZ. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes2009;1(1):9–17; doi: 10.1111/j.1753-0407.2009.00009.x
